Hemophilia B; | Stock Market News & Stocks to Watch from StraightStocks

PFE, PWRM, BIIB, DrStockPick.com Stock Report!

Dr. Stock Pick (October 19th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

PFE, PWRM, BIIB

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase

...

Tags for this Post:
advertisement services, ALS, Beijing, BIIB, Biogen Idec Inc., Biovitrum AB, Breast Cancer, broker, cancer, Chair and Keynote Speaker, chief scientific officer, China, Congress, CP-690, Crown Equity Holdings Inc.;, diagnostic tests, Dr Stock Pick, equity trader, Fda, hemophilia B;, Houston, innovative therapies, International Congress, Investing Lessons, Ira Goldknopf, JAK, Lymphoma, Multiple Sclerosis, neurodegenerative disease;, Pfizer Inc, Philadelphia, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, president, professional investment analyst and consultant, Rheumatoid Arthritis, stock featured on our site;, Stock Pick, Stocks to Watch, Texas, www.crowntradingsystems.com, www.crwenews.com, www.drstockpick.com, www.power3medical.com, www.stock-ir.com

Posted in Investing Lessons, Stocks to Watch | No Comments »

DrStockPick.com Stock Report! 10/19/09, 10/19/09, CSRH. ERIC, BX, AMD, BIIB, CVX

Dr. Stock Pick (October 19th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings, Inc. (OTCBB: CSRH) has launched its mobile check cashing program. The introduction of this service will offer those that are currently using check cashing facilities a much more convenient way to cash their payroll checks. After two years of development with its partners, Consorteum has now proceeded to the pilot phase of its check cashing program in the Toronto, Ontario region. The first stage of the pilot implementation will be the deployment of this new service on

...

Tags for this Post:
11 technology, Advanced Micro Devices Inc, advertisement services, advertising services, Australia, Biogen Idec, Biovitrum AB, Blackstone Group, British Land Company PLC, chevron corp, China, Consorteum Holdings Inc.;, Crown Equity Holdings Inc.;, Dr Stock Pick, Ericsson, european commission, gas field, Gorgon, hemophilia B;, Investing Lessons, London, microsoft, Microsoft Windows, mobile applications;, Natural Gas, Ontario, real-time check cashing services, social networking site, stock featured on our site;, Stocks to Watch, The Broadgate Estate, Toronto, USD

Posted in Investing Lessons, Stocks to Watch | No Comments »

Biogen Too Attractive to Ignore – Analyst Blog

Zacks Market Commentaries (February 6th, 2009) Writes:

Highlighted companies include Biogen Idec (BIIB), Genentech (DNA), Merck (MRK) and Sanofi-Aventis (SNY).At 13x our 2009 EPS of $4.05 per share, we believe that Biogen Idec's (BIIB) stock is too attractive to ignore. Valuation is below the biotech peer-group average, where several names are trading at a significant premium.The company should post non-GAAP EPS up roughly 11% in 2009, even with all the Tysabri PML issues. However, valuation alone is not enough of a reason to buy the stock. We are comfortable with owning the name here based on two other reasons.Firstly, Biogen has a significant late-stage pipeline. There are 22 programs in phase II or beyond. Six of these products are in phase III registration programs right now: lumiliximab for chronic lymphocytic leukemia (CLL), galiximab for non-Hodgkin's lymphoma (NHL), BG-12 for relapsing / remitting multiple sclerosis (RR-MS), ...

Tags for this Post:
Aventis, Biogen Idec, Biotechnology, biotechnology products;, Blog, Carl Icahn, chronic lymphocytic leukemia, CLL-08;, congestive heart failure;, gastrointestinal stromal tumors;, Genentech, hemophilia B;, hyponatremia;, large pharmaceutical, large-cap pharmaceutical, lupus nephritis;, Multiple Sclerosis, non-Hodgkin's lymphoma;, ovarian cancer, Parkinson's disease, Pfizer, Rheumatoid Arthritis, Rituxan;, Stocks to Watch, United States, USD, West Coast, Wyeth, Zacks Market Commentaries

Posted in Stocks to Watch | No Comments »

Biogen-Idec (NASDAQ:BIIB): Upgraded to Buy at Goldman Sachs

Notable Calls (January 27th, 2009) Writes:

div style="text-align: justify;"Goldman Sachs is upgrading span style="font-weight: bold;"Biogen-Idec (NASDAQ:BIIB)/span to Buy from Neutral and adding the stock to their Conviction Buy list with a $61 tgt (up from $57).br /br /According to the firm this is based on potential upside revision to earnings and attractive valuation. They believe the threat of generics and competition should be manageable, leading to their 2009/2010 EPS (incl. ESO) of $4.14 amp; $4.55 vs. consensus of $3.97 and $4.23, resp. BIIB’s pipeline is underestimated and should gain visibility in 2009/2010. The product profile and manufacturing capacity might be attractive for potential pharma acquirers. The intrinsic value of $46 implies a pipeline value of $3 which the firm views as attractive.br /br /span style="font-weight: bold;"Catalyst/spanbr /span style="font-weight: bold;"/spanbr /1) Safety data from over 10,000 patients on Tysabri therapy by yearend.br /br /2) In 2009, MLCO expects Phase 3 data on Rituxan in lupus nephritis (1Q, ...